Minerva Neurosciences, Inc: Minerva Neurosciences Reports Se

Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused

Related Keywords

Fred Ahlholm , Helen Shik , Remy Luthringer , Minerva Neurosciences , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Company Continues To Prepare For Potential Submission , Nasdaq , Company Continues , Potential Submission , Third Quarter , Drug Administrationon April , New Drug Applicationon April , Executive Chairman , Chief Executive Officer , Week Open Label Extension , Interest Expense , Future Royalties , Royalty Pharma , Private Securities Litigation Reform Act , Term Liabilities , Months Ended June , Aminerva , Neurosciences , Reports , Second , Quarter , 022 , Financial , Results , Business , Updates ,